1 |
S. Lewis, "Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?", American Heart Journal, Vol, 153(2), pp. 182-188, 2007. DOI: http://dx.doi.org/10.1016/j.ahj.2006.10.034
DOI
ScienceOn
|
2 |
T. D. Filippatos, E. N. Liberopoulos, N. Pavlidis, et al. "Effects of hormonal treatment on lipis in patients with cancer". Cancer Treatment Reviews, Vol, 35(2), pp. 175-84, 2009. DOI: http://dx.doi.org/10.1016/j.ctrv.2008.09.007
DOI
ScienceOn
|
3 |
T. Tominaga, I. Kimijima,, M, Kimura, et al. "Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer : Interim results from a Japanese Phase III trial", Japan Journal of Clinical Oncology, Vol, 40(7), pp. 627-633, 2010. DOI: http://dx.doi.org/10.1093/jjco/hyq021
DOI
ScienceOn
|
4 |
S. H. Jee, J. W. Song, H. K. Cho, et al. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea", Journal of Korean Lipid and Atherosclerosis, Vol, 14(2), pp. 153-168, 2004.
|
5 |
W. B. Kannel, D. McGee, T. Gordon, "A general cardiovascular risk profile: The Framingham Study", The American Journal of Cardiology, Vol, 38(1), pp. 46-51, 1976. DOI: http://dx.doi.org/10.1016/0002-9149(76)90061-8
DOI
ScienceOn
|
6 |
American Joint Committee on Cancer(AJCC), "Cancer staging manual. Sixth ed", Philadelphia(PA), Lippincott Raven Publishers, 2002.
|
7 |
National Institute of Health, "The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure", NIH Publication No. 03-5233, 2003.
|
8 |
L. Mosca, H. Mochari, A. Christina, et al. "National study of women's awareness, preventive action, and barriers to cardiovascular health". Circulation, Vol, 113(4), pp. 525-534, 2006. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.105. 588103
DOI
ScienceOn
|
9 |
Koran Society of Lipidology and Atherosclerosis. "Dyslipidemia treatment guideline, 2nd edition", pp. 6, 2009.
|
10 |
S. Moorjani, A. Dupont, F. Labrie, et al. "Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide", The Journal of Clinical Endocrinology and Metabolism, Vol, 66(2), pp. 314-322, 1988. DOI: http://dx.doi.org/10.1210/jcem-66-2-314
DOI
|
11 |
E. J. Schaefer, D. M. Foster, L. A. Zech, et al. "The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females", The Journal of Clinical Endocrinology and Metabolism, Vol, 57(2), pp. 262-267, 1983. DOI: http://dx.doi.org/10.1210/jcem-57-2-262
DOI
|
12 |
H. J. Milionis, E. N. Liberopoulos, M. S. Elisaf, "Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus", Diabetes and Metabolism, Vol, 27, pp. 160-163, 2001.
|
13 |
M. Elisaf, E. Bairaktari, N. Pavlidis, "The influence of tamoxifen on serum triglycerides", Breast, Vol, 9(4), pp. 238, 2000. DOI: http://dx.doi.org/10.1054/brst.1999.0129
DOI
ScienceOn
|
14 |
Y. Hozumi, M. Kawano, T. Saito, et al. "Effect of tamoxifen on serum lipid metabolism", The Journal of Clinical Endocrinology and Metabolism, Vol, 83(5), pp. 1633-163, 1998. DOI: http://dx.doi.org/10.1210/jc.83.5.1633
DOI
|
15 |
Korean Breast Cancer Society, "2006-2008 Breast cancer facts & figures", pp. 2-14, 2008.
|
16 |
National Institute of Health. "Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report", Circulation, Vol, 17(24), pp. 3145-3421, 2002.
|
17 |
National Cancer Center, "Cancer facts & figures", pp. 8, 2012.
|
18 |
A. Jemal, R. Siegel, E. Ward, et al, "Cancer statistics, 2006" CA: Cancer Journal for Clinicians, Vol, 56(2), pp. 106-130, 2006. DOI: http://dx.doi.org/10.3322/canjclin.56.2.106
DOI
ScienceOn
|
19 |
A. Howell, J. Cuzick, M. Baum, et al, "Results of the ATAC (Arimidex, Tamoxifen, Alone or Combination) trial after completion of 5years' adjuvant treatment for breast cancer", Lancet, Vol, 365(9453), pp. 60-62, 2005. DOI: http://dx.doi.org/10.1016/S0140-6736(04)17666-6
DOI
ScienceOn
|
20 |
D. N. Lloyd-Jones, A. R. Dyer, R. Wang, et al. "Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death(Chicago Heart Association Detection Project in Industry)", American Journal of Cardiology, Vol, 99(4), pp. 535-540, 2007. DOI: http://dx.doi.org/10.1016/j.amjcard.2006.09.099
DOI
ScienceOn
|
21 |
D. Steinberg, J. L. Witztum, "Lipoproteins and atherogenesis; Current concepts:, The Journal of the American Medical Association, Vol, 264(23), pp. 3047-3052, 1990. DOI: http://dx.doi.org/10.1001/jama.264.23.3047
DOI
ScienceOn
|
22 |
W. B. Kannel, W. P. Castelli, T. Gordon, et al. "Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study", Ann Intern Med, 74(1), pp. 1-12, 1971. DOI: http://dx.doi.org/10.7326/0003-4819-74-1-1
DOI
ScienceOn
|
23 |
R. J. Glynn, G. J. L'Italien, H. D. Sesson, et al, "Development of predictive models for longterm cardiovascular risk associated with systolic and diastolic blood pressure", Hypertension, Vol, 39(1), pp. 105-110, 2002. DOI: http://dx.doi.org/10.1161/hy1201.097199
DOI
ScienceOn
|
24 |
World Health Organization, "World Cancer Report 2008", pp. 212-213, 2010.
|
25 |
K. M. Anderson, P. M. Odell, P. W. F. Wilson, et al, "Cardiovascular disease risk profiles", American Heart Journal, Vol, 121, pp. 293-298, 1990. DOI: http://dx.doi.org/10.1016/0002-8703(91)90861-B
DOI
ScienceOn
|